Evidence map›Paper›PMID 35527932›Full record

ArticleRSC advances2019

Inhibitor-conjugated harmonic nanoparticles targeting fibroblast activation protein.

Raphaël De Matos, Jérémy Vuilleumier, Christophe Mas, Samuel Constant, Davide Staedler, Sandrine Gerber-Lemaire

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Raphaël De MatosInstitute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, Group for Functionalized Biomaterials EPFL SB ISIC SCI-SB-SG, Station 6 CH-1015 Lausanne Switzerland Sandrine.Gerber@epfl.ch.
Jérémy VuilleumierInstitute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, Group for Functionalized Biomaterials EPFL SB ISIC SCI-SB-SG, Station 6 CH-1015 Lausanne Switzerland Sandrine.Gerber@epfl.ch.
Christophe MasOncotheis 18 chemin des Aulx, CH-1228 Plan-les-Ouates Geneva Switzerland.
Samuel ConstantOncotheis 18 chemin des Aulx, CH-1228 Plan-les-Ouates Geneva Switzerland.
Davide StaedlerDepartment of Pharmacology and Toxicology, Faculty of Biology and Medicine, University of Lausanne Lausanne CH-1011 Switzerland.ORCID https://orcid.org/0000-0002-1602-0677
Sandrine Gerber-LemaireInstitute of Chemical Sciences and Engineering, Ecole Polytechnique Fédérale de Lausanne, Group for Functionalized Biomaterials EPFL SB ISIC SCI-SB-SG, Station 6 CH-1015 Lausanne Switzerland Sandrine.Gerber@epfl.ch.ORCID https://orcid.org/0000-0002-6519-2782
Charles Humbert 8 · CHExelixis (United States) · USFaculty (United Kingdom) · GBOncotherapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The recent progress in the engineering of nanosized inorganic materials presenting tailored physical properties and reactive surface for post-functionalization has opened promising avenues for the use of nanoparticles (NPs) in diagnosis and therapeutic intervention. Surface decoration of metal oxide NPs with ligands modulating circulation time, cellular uptake, affinity and extravasation through active targeting led to efficient cancer specific bioimaging probes. The most relevant cancer biomarkers studied so far include surface and transmembrane cancer cell receptors. More recently, tumor microenvironments and more specifically the fibroblastic element of the tumor stroma have emerged as a valuable target for diagnosis and treatment of several types of cancers. In this study, a low molecular weight ligand targeting fibroblast activation protein α (FAP), which is specifically expressed by activated fibroblasts of the tumor stroma, was synthesized. This ligand demonstrated nanomolar inhibition of FAP with high selectivity with respect to prolyl oligopeptidase (PREP) and dipeptidyl peptidase (DPP) IV, as well as good biocompatibility toward a human lung tissue model. Bismuth ferrite (BFO) harmonic nanoparticles (HNPs) conjugated to this ligand showed target-specific association to FAP as demonstrated by reverse ELISA-type assay using Human Fibroblast Activation Protein alpha/FAP Alexa Fluor® 594-conjugated Antibody and multiphoton multispectral microscopy experiments. These functionalized HNPs may provide new nanocarriers to explore the role of FAP in tumorigenesis and to target the fibroblastic component of the tumor microenvironment.

Identifiers

PMID35527932
PMCPMC9072645
OpenAlexW2978386605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.